Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon L Amidon

Showing results (1-10 of 185) with videos related to

Pageof 19
Sort By:
Molecular Pharmaceutics|July 20, 2005
Molecular pharmaceutics: the NIH Roadmap and the FDA pipeline problemGordon L Amidon
Molecular Pharmaceutics|April 5, 2005
Collaborative research trainingGordon L Amidon
Molecular Pharmaceutics|April 19, 2005
Finding the "Magic"Gordon L Amidon
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 23, 2009
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targetingArik Dahan, Gordon L Amidon
International Journal of Pharmaceutics|December 1, 2009
MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targetingArik Dahan, Gordon L Amidon
Molecular Pharmaceutics|June 19, 2010
The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulationYasuhiro Tsume, Gordon L Amidon
Molecules (Basel, Switzerland)|March 28, 2012
The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzymeYasuhiro Tsume, Gordon L Amidon
Molecular Pharmaceutics|March 6, 2018
Pulse Packet Stochastic Model for Gastric Emptying in the Fasted State: A Physiological ApproachArjang Talattof, Gordon L Amidon
Pharmaceutical Research|December 3, 2008
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoproteinArik Dahan, Gordon L Amidon
Molecular Pharmaceutics|February 28, 2009
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugsArik Dahan, Gordon L Amidon
Pageof 19

Showing results (1-10 of 185) with videos related to

Sort By:
Pageof 19
Molecular Pharmaceutics|July 20, 2005
Molecular pharmaceutics: the NIH Roadmap and the FDA pipeline problemGordon L Amidon
Molecular Pharmaceutics|April 5, 2005
Collaborative research trainingGordon L Amidon
Molecular Pharmaceutics|April 19, 2005
Finding the "Magic"Gordon L Amidon
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 23, 2009
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targetingArik Dahan, Gordon L Amidon
International Journal of Pharmaceutics|December 1, 2009
MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targetingArik Dahan, Gordon L Amidon
Molecular Pharmaceutics|June 19, 2010
The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulationYasuhiro Tsume, Gordon L Amidon
Molecules (Basel, Switzerland)|March 28, 2012
The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzymeYasuhiro Tsume, Gordon L Amidon
Molecular Pharmaceutics|March 6, 2018
Pulse Packet Stochastic Model for Gastric Emptying in the Fasted State: A Physiological ApproachArjang Talattof, Gordon L Amidon
Pharmaceutical Research|December 3, 2008
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoproteinArik Dahan, Gordon L Amidon
Molecular Pharmaceutics|February 28, 2009
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugsArik Dahan, Gordon L Amidon
Pageof 19